Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Year of publication
- 2017 (21) (remove)
Document Type
- Journal article (16)
- Doctoral Thesis (5)
Keywords
- medicine (4)
- CXCR4 (3)
- multiple myeloma (3)
- Aspergillus fumigatus (2)
- FDG (2)
- PET (2)
- PET/CT (2)
- fungal infection (2)
- theranostics (2)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Allogene hämatopoetische Stammzelltransplantation (1)
- Aluminiumhydroxid (1)
- Aluminiumhydroxide (1)
- Antitumorforschung (1)
- Aspergillose (1)
- Autoimmuntherapie (1)
- Bone marrow transplantation (1)
- Cancer (1)
- Cancer risk factors (1)
- Chronic lymphoblastic leukemia (1)
- Chronic myeloid leukemia (1)
- DExD/H-Box RNA helicase (1)
- DOTATOC (1)
- EndoVAC and small bowel (1)
- Entwicklung (1)
- Enzyme Regulation (1)
- Graft-versus-Leukämie-Effekt (1)
- HECT Ligase (1)
- HLA-E matching (1)
- HSTC outcome (1)
- HUWE1 (1)
- Hematopoietic stem cell transplantation (1)
- Immune receptor signaling (1)
- Immunotherapy (1)
- Immunsystem (1)
- Immuntherapie (1)
- Killer cell immunoglobulin-like receptors (1)
- Klonierung (1)
- Medicine (1)
- Molecular Biophysics (1)
- Multivariate analysis (1)
- NFATc1 (1)
- NK-cells (1)
- P14ARF (1)
- PRRT (1)
- Periphere Stammzellentransplantation (1)
- Positronen-Emissions-Tomografie (1)
- RIG-I (1)
- Resiquimod (1)
- SSTR (1)
- STAT1 (1)
- Schwangerschaft (1)
- Stem cell transplantation (1)
- Strategies to Obtain Tumor-Reactive Cells (1)
- Structural Biology (1)
- T-cells (1)
- TNF (1)
- TNFR2-spezifische Agonisten (1)
- Transplantat-Wirt-Reaktion (1)
- Trypanosoma (1)
- Tumorantigen (1)
- Tumorassoziierte Antigene (1)
- Ubiquitin (1)
- X-Ray Chrystallography (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-methionine (1)
- acute leukemia (AL) (1)
- allogeneic hematopoietic stem cell transplantation (1)
- biophysics (1)
- bone marrow (1)
- breast cancer (1)
- cell cycle (1)
- chemokine receptor (1)
- circulating (1)
- circulating tumor cells (1)
- colorectal cancer (1)
- comprehensive management (1)
- cytokinesis (1)
- cytotoxic T cells (1)
- duodenal perforation (1)
- duodenal trauma (1)
- fear of progression (1)
- gastrointestinal tumors (1)
- gastrointestinale Tumore (1)
- gene regulation (1)
- graft-versus-leukemia effect (1)
- hematopoietic stem cell transplantation (HSCT) (1)
- human leukocyte antigen-E (HLA-E) (1)
- humans (1)
- immune cells (1)
- immunotherapy (1)
- innate immune response (1)
- innate immunity (1)
- kinesin (1)
- lymphocyte activation (1)
- megakaryocytes (1)
- microswimmer (1)
- molecular imaging (1)
- murine model (1)
- natural killer cells (1)
- neuroendocrine tumor (1)
- none (1)
- oncostatin M (1)
- oral anticancer drugs (1)
- pattern recognition receptors (1)
- peptide receptor radionuclide therapy (1)
- pregnancy (1)
- radionuclide therapy (1)
- screening for distress (1)
- signal transduction (1)
- sleeping sickness (1)
- structural biology (1)
- thrombopoiesis (1)
- transstomal endoluminal vacuum therapy (1)
- tsetse fly (1)
- tumor-associated antigens (1)
- zirkulierende Tumorzellen (1)
Institute
- Medizinische Klinik und Poliklinik II (21) (remove)
EU-Project number / Contract (GA) number
- 701983 (1)
Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance of the CXCR4-directed radiotracer [\(^{68}\)Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies.
Thirty-five patients with MM underwent [\(^{68}\)Ga]Pentixafor-PET/CT for evaluation of eligibility for endoradiotherapy. In 19/35 cases, [\(^{18}\)F]FDG-PET/CT for correlation was available. Scans were compared on a patient and on a lesion basis. Tracer uptake was correlated with standard clinical parameters of disease activity.
[\(^{68}\)Ga]Pentixafor-PET detected CXCR4-positive disease in 23/35 subjects (66%). CXCR4-positivity at PET was independent from myeloma subtypes, cytogenetics or any serological parameters and turned out as a negative prognostic factor. In the 19 patients in whom a comparison to [\(^{18}\)F]FDG was available, [\(^{68}\)Ga]Pentixafor-PET detected more lesions in 4/19 (21%) subjects, [\(^{18}\)F]FDG proved superior in 7/19 (37%). In the remaining 8/19 (42%) patients, both tracers detected an equal number of lesions. [\(^{18}\)F]FDG-PET positivity correlated with [\(^{68}\)Ga]Pentixafor-PET positivity (p=0.018).
[\(^{68}\)Ga]Pentixafor-PET provides further evidence that CXCR4 expression frequently occurs in advanced multiple myeloma, representing a negative prognostic factor and a potential target for myeloma specific treatment. However, selecting patients for CXCR4 directed therapies and prognostic stratification seem to be more relevant clinical applications for this novel imaging modality, rather than diagnostic imaging of myeloma.